Johnson & Johnson - HealthQuill

Johnson & Johnson MedTech’s arm, Shockwave Medical Inc. has started human trials to assess the effectiveness of its coronary intravascular catheter for treating blocked arteries, according to a statement.

J&J starts trial on coronary pressure wave catheter to clear artery blocks

HQ Team April 13, 2025: Johnson & Johnson MedTech’s arm, Shockwave Medical Inc. has started human trials to assess the effectiveness of its.

by HealthQuill
April 13, 2025
0 Comments

Johnson & Johnson plans to acquire Israel’s privately-held V-Wave Ltd., for an upfront payment of $600 million, according to a statement from the US-based company.

Drugs Pharma

Johnson & Johnson ends late-stage trial of depression drug aticaprant

HQ Team March 7, 2025: Johnson & Johnson is discontinuing the Phase 3 VENTURA clinical trial of its experimental depression drug aticaprant after.

by HealthQuill
March 7, 2025
0 Comments

Johnson & Johnson will acquire Intra-Cellular Therapies Inc., a biopharmaceutical company developing drugs for central nervous system disorders, for $14.6 billion, according to a J&J statement.

Drugs Medical Pharma

Johnson & Johnson to acquire Intra-Cellular Therapies Inc., for $14.6 billion

Johnson & Johnson will acquire Intra-Cellular Therapies Inc., a biopharmaceutical company developing drugs for central nervous system disorders, for $14.6 billion, according to.

by HealthQuill
January 14, 2025
0 Comments

ohnson & Johnson paused its rollout of a heart device to treat atrial fibrillation “out of an abundance of caution,” as it probes four cases of neurovascular events related to the device.

Health Medical Pharma

J&J pauses rollout of heart device in US after ischemic, stroke incidents

ohnson & Johnson paused its rollout of a heart device to treat atrial fibrillation “out of an abundance of caution,” as it probes four.

by HealthQuill
January 10, 2025
0 Comments

Johnson & Johnson’s combination therapy for treating a certain form of cancer without chemotherapy, has been shown to extend patients' lives by more than a year, according to a company statement.

Drugs Health Medical Pharma

J&J’s combination extends lives of cancer patients versus rival drug

Johnson & Johnson’s combination therapy for treating a certain form of cancer without chemotherapy, has been shown to extend patients' lives by more.

by HealthQuill
January 8, 2025
0 Comments

Johnson & Johnson has discontinued its mid-stage trial, evaluating an antiviral drug, mosnodenvir, for the prevention of dengue.

Drugs Health Pharma

Johnson & Johnson stops mid-stage trial of drug for dengue prevention

Johnson & Johnson has discontinued its mid-stage trial, evaluating an antiviral drug, mosnodenvir, for the prevention of dengue.

by HealthQuill
October 5, 2024
0 Comments

Johnson & Johnson will invest $2 billion to build a biologics manufacturing facility in Wilson, North Carolina, anticipating new products planned by the decade's end.

Drugs Health Pharma

J&J to build $2b facility in North Carolina to make future products

HQ Team October 2, 2024: Johnson & Johnson will invest $2 billion to build a biologics manufacturing facility in Wilson, North Carolina, anticipating.

by HealthQuill
October 2, 2024
0 Comments

Drugs Health Pharma

J&J plans to acquire Israel’s V-Wave by paying $600 million upfront

Johnson & Johnson plans to acquire Israel’s privately-held V-Wave Ltd., for an upfront payment of $600 million, according to a statement from the.

by HealthQuill
August 20, 2024
0 Comments

Johnson & Johnson will acquire Proteologix, Inc., a privately-held biotechnology company, for $850 million in cash, according to a statement.

Drugs Health Pharma

Johnson & Johnson to buy Proteologix Inc., for $850 million in cash

HQ Team May 17, 2024: Johnson & Johnson will acquire Proteologix, Inc., a privately-held biotechnology company, for $850 million in cash, according to.